Drug Profile
BC 3205
Alternative Names: BC-3205Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Nabriva Therapeutics
- Class Antibacterials
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Pneumonia; Skin and soft tissue infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pneumonia in Austria (IV)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Pneumonia in Austria (PO)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Skin-and-soft-tissue-infections in Austria (IV)